NewAmsterdam Pharma CAO to depart with severance

NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026.

Rhea-AI Filing Summary

NewAmsterdam Pharma Company N.V. reports that Chief Accounting Officer Louise Kooij will end her employment effective August 31, 2026. The company and Ms. Kooij entered into a separation agreement on April 24, 2026.

Under this agreement, she is eligible for a lump-sum payment equal to twelve months of her current base salary, a pro-rated 2026 annual cash bonus based on target achievement through the separation date, and payment for accrued but unused holiday and vacation days in line with Dutch law.

The company will extend vesting of her outstanding stock options and RSU awards through January 10, 2027, and vested stock options will remain exercisable until February 10, 2027. The agreement also includes confidentiality, non-compete and non-disparagement covenants and a release of claims, and is expected to be filed with the company’s Form 10-Q for the quarter ending June 30, 2026.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Severance duration: 12 months of base salary Bonus treatment: Pro-rated 2026 annual bonus Equity vesting extension: Through January 10, 2027 +1 more

4 metrics

Severance duration 12 months of base salary Lump-sum payment under separation agreement

Bonus treatment Pro-rated 2026 annual bonus Based on target achievement through separation date

Equity vesting extension Through January 10, 2027 Outstanding stock options and RSU awards

Option exercise deadline February 10, 2027 Expiration of vested stock options exercise period

Key Terms

separation agreement, restricted stock unit, non-compete, release of claims

4 terms

separation agreement financial

"On April 24, 2026, Ms. Kooij and the Company entered into a separation agreement"

A separation agreement is a written contract that spells out the financial and legal terms when an employee and a company part ways, such as final pay, severance, continued benefits, confidentiality, and any release of claims. For investors, it matters because these agreements determine immediate costs, potential future liabilities, and whether departing staff are restricted from competing or disclosing information—factors that can affect a company’s cash flow, risk profile, and leadership continuity.

restricted stock unit financial

"outstanding stock options and restricted stock unit (“RSU”) awards through January 10, 2027"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

non-compete financial

"The Separation Agreement contains restrictive covenants, including confidentiality, non-compete and non-disparagement covenants"

A non-compete is a contract clause that prevents an employee, executive, or seller from working for or starting a rival business for a set time and area after leaving a company. It matters to investors because it protects the value of intellectual property, customer relationships and key personnel—like putting a temporary fence around a company’s customers and know‑how—while also creating legal and operational constraints that can affect talent mobility and deal attractiveness.

release of claims financial

"The Separation Agreement contains restrictive covenants ... and a release of claims"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NewAmsterdam Pharma (NAMS) disclose about its Chief Accounting Officer?

NewAmsterdam Pharma disclosed that Chief Accounting Officer Louise Kooij will end her employment on August 31, 2026. The company entered into a separation agreement with her on April 24, 2026, outlining severance, bonus, equity vesting, and related covenants.

What severance payments will Louise Kooij receive from NewAmsterdam Pharma (NAMS)?

Louise Kooij is eligible for a lump-sum payment equal to twelve months of her current base salary. She will also receive a pro-rated 2026 annual cash bonus reflecting target achievement through her separation date, plus payment for accrued but unused holiday and vacation days under Dutch law.

How are NewAmsterdam Pharma (NAMS) equity awards for Louise Kooij treated in the separation agreement?

The separation agreement extends vesting of Louise Kooij’s outstanding stock options and RSU awards through January 10, 2027. In addition, the exercise period for each vested stock option she holds will expire on February 10, 2027, giving additional time to exercise vested options.

What restrictive covenants apply to Louise Kooij after leaving NewAmsterdam Pharma (NAMS)?

The separation agreement includes confidentiality, non-compete, and non-disparagement covenants, as well as a release of claims. These provisions are designed to govern Ms. Kooij’s conduct after her departure and to settle potential employment-related claims between her and the company.

When will NewAmsterdam Pharma (NAMS) file the full separation agreement with the SEC?

The company intends to file the full separation agreement with its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026. Investors will be able to review the complete terms once that report is submitted to the SEC.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/24/2026 - 04:30 PM EDT Learn about SEC filing dates

0001936258false00-000000000019362582026-04-202026-04-200001936258us-gaap:CommonStockMember2026-04-202026-04-200001936258us-gaap:WarrantMember2026-04-202026-04-20

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 20, 2026

NewAmsterdam Pharma Company N.V.

(Exact name of Registrant as Specified in Its Charter)

The Netherlands			001-41562	N/A
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
Goomieer 2-35
Naarden
The Netherlands				1411 DC
(Address of Principal Executive Offices)				(Zip Code)
			+31 (0) 35 206 2971
(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary shares, nominal value €0.12 per share		NAMS		The Nasdaq Stock Market LLC
Warrants to purchase ordinary shares		NAMSW		The Nasdaq Stock Market LLC

☐	Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
☐	If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

On April 20, 2026, NewAmsterdam Pharma Company N.V. (the “Company”) and Louise Kooij agreed that her employment as the Company's Chief Accounting Officer would end effective August 31, 2026 (the “Separation Date“). On April 24, 2026, Ms. Kooij and the Company entered into a separation agreement (the “Separation Agreement”). Pursuant to the Separation Agreement, following the Separation Date, Ms. Kooij is eligible to receive payment of (i) a lump sum equal to twelve months of her base salary as currently in effect, (ii) a pro-rated 2026 annual cash bonus, which payment is representative of target achievement of Ms. Kooij’s annual bonus through the Separation Date; and (iii) any accrued but unused holiday and vacation days as of the Separation Date, in accordance with Dutch law. In addition, pursuant to the Separation Agreement, the Company agreed (i) to extend the vesting of Ms. Kooij’s outstanding stock options and restricted stock unit (“RSU”) awards through January 10, 2027, and (ii) that the exercise period for each vested stock option held by Ms. Kooij will expire on February 10, 2027. The Separation Agreement contains restrictive covenants, including confidentiality, non-compete and non-disparagement covenants, and a release of claims.

The foregoing description of the Separation Agreement is a summary only and is qualified by reference in its entirety to the Separation Agreement, a copy of which the Company intends to file with its Quarterly Report on Form 10-Q for the quarter ending June 30, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			NewAmsterdam Pharma Company N.V.
Date:	April 24, 2026	By:	/s/ Mike Marino
		Name:	Mike Marino
		Title:	Chief Legal Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 53.7 KB